KDM1A and acute myeloid leukemia: Several studies have shown that LSD1 is a prominent driver of the non-APL AML differentiation block, and that LSD1 inhibitors (LSD1i) induce varying degrees of differentiation in a variety of AML mutational subtypes8–10.